Ipca Laboratories and Heritage Pharmaceuticals Inc have launched Propranolol tablets in US after receiving necessary approval from US FDA for manufacture and marketing Propranolol HCI tablets in 10, 20, 40, 60 and 80 mg strength.
These tablets have multiple cardiovascular related indications, including the management of hypertension, treatment of angina and a trial fibrillation. As per the IMS Health report Propranolol had US brand and generic sales of approximately $25 million for the year ended December 2007.
Ipca and Heritage have entered into a strategic alliance under which Ipca will manufacture and Heritage will market this formulation in the US healthcare system using Ipca's DMF approved API – Propranolol. Heritage will commercialise this product in the US market utilizing its established marketing expertise and distribution network.
Heritage Pharmaceuticals Inc is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing sale and distribution of generic pharmaceutical products for the global prescription drug markets.
Heritage launched its US label in 2006 and currently markets 5 products over 17 SKU's, including Ethambutol oral tablets, Hydralazine oral tablets, Bydrochlorothiazide oral tablets, etc. Heritage's business model utilizes strategic outsourcing to USFDA qualified manufacturing and development organizations in both North America and Asia.